Pharmacy Law and Controlled Substance Regulation

Professional Judgment and Regulatory Oversight in Pharmacy

• Clinical Decision-Making: Pharmacists must exercise significant professional judgment and clinical decision-making when entering and verifying prescriptions.
• Law and Ethics Integration: Legal requirements are an inherent part of the community pharmacy process. Pharmacy laws and ethics often contain "gray areas" that are not always clear-cut, requiring interpretation and sometimes consultation with regulatory boards.
• Vagueness in Regulations: Laws may be written vaguely, leading to differing views among pharmacists. Professionals often rely on resources like Board of Pharmacy inspectors to navigate complex legal scenarios.
• Food and Drug Administration (FDA): Primarily involved in the safety and efficacy of drugs. They create and uphold regulations to protect public safety.
• Drug Enforcement Administration (DEA): Enforces laws related to controlled substances.
• Federal vs. State Law: State laws may differ from federal laws. In cases of conflict, pharmacists must always follow the more stringent (stricter) law.

Patient Privacy and Information Disclosure

• Health Insurance Portability and Accountability Act (HIPAA): Established in the 1990s to set privacy and security requirements for health care providers.
• Notice of Privacy Practices: Patients are required to acknowledge these practices, often through electronic initials or signatures on a pen pad.
• National Provider Identifier (NPI): A requirement established under HIPAA that providers must use to bill insurance.
• Protected Health Information (PHI) Disclosure:
  • Provider-to-Provider: PHI can be disclosed without explicit patient approval to other providers involved in the patient's care (mutual patients).
  • Insurance Companies: DISCLOSURE is permitted for joint efforts, such as billing dates or diagnostic information.
  • Law Enforcement: DEA or police may request information for investigations. Pharmacists should document the process and may consult legal teams before releasing data.
  • Attorneys: Legal representatives (e.g., for accident cases) cannot receive PHI without explicit patient approval.
  • Custodian of Records: Large organizations often have dedicated departments or legal teams to handle the documentation and approval of record disclosures.

Fundamentals of Controlled Substances

• Classification (Schedules I-V): Controlled substances are grouped by their potential for abuse. The lower the number, the higher the abuse potential. "Schedule" and "C" (e.g., C-II, C-III) are used interchangeably.
  • Schedule I (C-I): No accepted medical use; illicit drugs.
  • Schedules II through V (C-II to C-V): Acceptable for medical use in pharmacy practice.
• Manufacturer Labeling: All federally controlled substances must have a prominent mark/designation on the label indicating their schedule.
• State-Specific Controls: Certain drugs may be controlled in specific states but not federally.
  • Example: Gabapentin is controlled in Kentucky but not in all other states. Consequently, it may not have a control designation on the manufacturer's label depending on the state of origin.

Inventory, Ordering, and Security Requirements

• Record Keeping: Accurate records of all controlled substance activity (ordering and inventory) are mandatory for distributors and pharmacies.
• Inventory Discrepancies: Physical counts must match records. Discrepancies must be investigated for miscounts, misplaced stock, or theft.
• Ordering C-II Substances:
  • DEA 222 Form: The traditional paper form for ordering Schedule II drugs.
  • CSOS (Controlled Substances Ordering System): The modern electronic equivalent used by most pharmacies to streamline record-keeping.
  • Verification: Upon receipt, the pharmacist must sign, date, and annotate the invoice to confirm the items received match the order.
• Security and Storage:
  • C-II Storage: Traditionally kept in a locked, tamper-proof safe or cabinet.
  • Interspersing: If not in a safe, controlled substances should be dispersed among non-controlled drugs on the pharmacy shelves to reduce the risk of large-scale theft/shrinkage. They should never be grouped together in one "control section" if not secured in a safe.
  • Professional Judgment: Pharmacists may choose to lock up non-C-II drugs (e.g., Suboxone) if they perceive a high risk of theft or shrinkage.

Pharmacist Responsibilities and Verification Processes

• Corresponding Responsibility: Pharmacists share liability with the prescriber. A prescription's validity depends on it being issued for a "legitimate medical purpose."
• Right to Refuse: Pharmacists can and should decline to fill prescriptions if they suspect illegality, lack of medical purpose, or patient safety issues (e.g., drug interactions).
• Due Diligence: This includes calling providers for diagnoses and checking state databases.
• Prescription Drug Monitoring Programs (PDMP):
  • Kentucky: KASPER (Kentucky All Schedule Prescription Electronic Reporting).
  • Indiana: INSPECT.
  • Verification: Kentucky pharmacists must attest to having a KASPER account during annual license renewal.
• Documentation: All consultations with providers regarding the validity or details of a script must be annotated on the prescription with the date and the name of the person spoken to.
• DEA Numbers: Pharmacies as entities must have a DEA number to dispense controls. Individual pharmacists do not need a personal DEA number for standard dispensing.

Technical Requirements for Prescription Blanks and E-Prescribing

• Kentucky Security Blanks:
  • Color: Must be "Pantone Green."
  • Security Features: Watermark (security line), specific size requirements, and quantity checkboxes.
  • Quantity Checkboxes: These serve as a secondary validation of the written quantity. If missing on a C-II script, it cannot be filled.
• Electronic Prescribing (E-Prescribing):
  • Kentucky Mandate: As of 2021, practitioners are required to use electronic prescribing for controlled substances.
  • Exceptions/Waivers: Providers may apply for annual waivers if they lack the software or face technical difficulties. The onus is on the provider to maintain the waiver, not the pharmacist to verify it for every script.
  • Digital Signatures: Electronic scripts for controls must include a specific digital signature annotation with a timestamp.

Legal Modifications to Schedule II (C-II) Prescriptions

• Prohibited Changes: A pharmacist may never change or add:
  • The patient's name.
  • The drug name.
  • The provider's signature.
  • The date of issue (if the year is wrong, e.g., writing the previous year in January, the script is invalid and must be reissued).
• Changes/Additions Requiring Provider Consultation:
  • Date of issue (if missing).
  • Drug strength.
  • Quantity (only if changed in conjunction with strength, not to exceed the total authorized dose).
  • Directions for use.
  • Quantity check-off box.
  • Refill instructions (only to clarify intent, as C-IIs cannot have refills).
  • Practitioner's printed name.
• Changes/Additions NOT Requiring Consultation (if obtainable elsewhere):
  • Patient address.
  • Dosage form (if obvious or only one exists).
  • Practitioner's address, phone number, and DEA number.

Practitioner Prescribing Authority and Limitations (Kentucky)

• Advanced Practice Registered Nurses (APRN/NP):
  • C-II Limitations: Generally 3-day supply for acute pain.
  • C-II Hydrocodone Exception: Can write up to a 30-day supply of hydrocodone-containing products (e.g., Norco).
  • C-II Psychostimulants: Can write a 30-day supply (e.g., Adderall, Vyvanse) if they are certified as a Psychiatric Mental Health Nurse Practitioner (PMHNP).
  • C-III: 30-day supply with no refills.
  • C-IV & C-V: 6-month supply (refills allowed).
• Physician Assistants (PA) (Per Senate Bill 116, effective July 2024):
  • C-II Limitations: Generally 72-hour supply.
  • C-II Hydrocodone/Non-Narcotics: Can write 30-day supplies for hydrocodone combination products and non-narcotic C-II controls (e.g., Adderall).
  • C-III: 30-day supply with no refills.
  • C-IV & C-V: 6-month supply for most, but no refills allowed on benzodiazepines (e.g., Diazepam, Xanax/Alprazolam) or Carisoprodol (Soma).

Prescription Validity and Expiration Periods

• Non-Controlled Prescriptions: Valid for 1 year from the date written.
• Schedules III-V: Valid for 6 months from the date written (cannot exceed 5 refills).
• Schedule II: Valid for 60 days from the date written in Kentucky.
• Postdating: Illegal. A provider cannot write a future date as the "written date." They must use the actual date of the encounter and may add a "Do not fill until" instruction.
• "Do Not Fill Until" Dates: These dates cannot be changed by a pharmacist, even with verbal authorization. A new prescription is required for an earlier fill.

Restricted Non-Controlled Substances

• Combat Methamphetamine Epidemic Act (CMEA): Regulates behind-the-counter sales of ephedrine, pseudoephedrine, and phenylpropanolamine.
• Sales Tracking: Sales are monitored through an electronic system (e.g., MethCheck) using patient ID.
• Kentucky Legal Limits:
  • Daily Limit: $3.6\,\text{g}$.
  • 30-Day Limit: $7.2\,\text{g}$.

Questions & Discussion

• Question: If a C-II script is missing the signature and the date, can the pharmacist fix it?
• Answer: The date can be added after calling the provider to verify. However, the signature cannot be added or changed; the script must be returned to the office for a physical signature or reissued electronically.
• Question: Can a pharmacist fill an out-of-state prescription (e.g., from Indiana) in Kentucky?
• Answer: Yes, but the pharmacist must ensure the prescription is legal in both the state of origin and Kentucky. Specifically, the pharmacist must follow Kentucky's stricter prescribing limits (e.g., if an Indiana NP writes a 30-day C-II script that is limited to 3 days in Kentucky, the pharmacist cannot fill it for 30 days).
• Question: Can a nurse practitioner (NP) write refills for a C-III drug like testosterone?
• Answer: No. In Kentucky, NPs are restricted to a 30-day supply with zero refills for C-III substances. Pharmacists often have to call the office to correct scripts where refills were erroneously included.
• Question: Does a PA's new authority to write C-IIs require a specific designation?
• Answer: Yes, they still operate under the supervision of a physician, but Senate Bill 116 expanded their ability to write 72-hour supplies of most C-IIs and 30-day supplies of others.